- Home
- LRMR vs FBRX Comparison
LRMR vs FBRX Comparison
Compare LRMR & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | FBRX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 487.2M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LRMR | FBRX |
|---|---|---|
| Price | $4.33 | $28.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $16.50 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.3M | 368.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,816.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.73 | $6.50 |
| 52 Week High | $6.42 | $35.80 |
Technical Indicators
Market Signals| Indicator | LRMR | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 47.69 |
| Support Level | $4.21 | $26.67 |
| Resistance Level | $4.45 | $31.71 |
| Average True Range (ATR) | 0.22 | 2.68 |
| MACD | -0.07 | -0.56 |
| Stochastic Oscillator | 14.21 | 22.88 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.